TABLE 1.
People characteristics in nested case–control analysis after matching
| Thrombocytopenia | Leukopenia | Neutropenia | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Case | SMD a | Control | Case | SMD | Control | Case | SMD | |
| People, n | 52 394 | 5538 | 18 310 | 1947 | 3284 | 349 | |||
| Mean age at onset (SD) | 66 (19.7) | 65 (19.5) | 0.016 | 57 (19.3) | 56 (19.0) | 0.009 | 52 (19.8) | 51 (19.7) | 0.005 |
| Male, n (%) | 27 130 (51.8) | 2911 (52.6) | 0.016 | 6602 (36.1) | 706 (36.3) | 0.004 | 1085 (33.0) | 118 (33.8) | 0.016 |
| Charlson's comorbidity index | 0.010 | 0.010 | 0.004 | ||||||
| 0 | 36 251 (69.2) | 3858 (69.7) | 14 852 (81.1) | 1587 (81.5) | 0 (0.0) | 0 (0.0) | |||
| 1–2 | 16 069 (30.7) | 1672 (30.2) | 3439 (18.8) | 358 (18.4) | 475 (14.5) | 50 (14.3) | |||
| 3–4 | 74 (0.1) | 8 (0.1) | 19 (0.1) | 2 (0.1) | 0 (0.0) | 0 (0.0) | |||
| ≥5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Medical history | |||||||||
| Congestive heart failure | 887 (1.7) | 160 (2.9) | 0.080 | 207 (1.1) | 35 (1.8) | 0.056 | 21 (0.6) | 6 (1.7) | 0.100 |
| Hypertension | 18 934 (36.1) | 1590 (28.7) | 0.159 | 4697 (25.7) | 354 (18.2) | 0.181 | 706 (21.5) | 43 (12.3) | 0.247 |
| Vascular disease | 3536 (6.7) | 398 (7.2) | 0.017 | 793 (4.3) | 72 (3.7) | 0.032 | 117 (3.6) | 7 (2.0) | 0.095 |
| Ischemic stroke | 1933 (3.7) | 177 (3.2) | 0.027 | 394 (2.2) | 21 (1.1) | 0.085 | 54 (1.6) | 4 (1.1) | 0.042 |
| Diabetes | 10 856 (20.7) | 981 (17.7) | 0.076 | 2284 (12.5) | 197 (10.1) | 0.074 | 349 (10.6) | 28 (8.0) | 0.090 |
| COPD | 1513 (2.9) | 97 (1.8) | 0.076 | 359 (2.0) | 38 (2.0) | 0.001 | 34 (1.0) | 5 (1.4) | 0.036 |
| Moderate–severe liver disease | 0 (0.0) | 4 (0.1) | 0.038 | 0 (0.0) | 0 (0.0) | <0.001 | 0 (0.0) | 0 (0.0) | <0.001 |
| Rheumatoid arthritis and SLE | 135 (0.3) | 12 (0.2) | 0.008 | 42 (0.2) | 21 (1.1) | 0.106 | 5 (0.2) | 5 (1.4) | 0.145 |
| Hyper−hypo‐thyroidism | 911 (1.7) | 121 (2.2) | 0.032 | 370 (2.0) | 74 (3.8) | 0.106 | 54 (1.6) | 29 (8.3) | 0.310 |
| Recent prescription (90 days prior) | |||||||||
| Lipid‐lowering agents | 14 389 (27.5) | 1260 (22.8) | 0.109 | 3231 (17.6) | 251 (12.9) | 0.132 | 461 (14.0) | 27 (7.7) | 0.203 |
| Anti‐arrhythmic drugs | 77 (0.1) | 58 (1.0) | 0.117 | 19 (0.1) | 5 (0.3) | 0.036 | 4 (0.1) | 1 (0.3) | 0.037 |
| Oral anticoagulants | 717 (1.4) | 82 (1.5) | 0.009 | 220 (1.2) | 15 (0.8) | 0.044 | 29 (0.9) | 7 (2.0) | 0.094 |
| Antiplatelets | 7272 (13.9) | 756 (13.7) | 0.007 | 1495 (8.2) | 157 (8.1) | 0.004 | 216 (6.6) | 21 (6.0) | 0.023 |
| Antidepressants | 2419 (4.6) | 208 (3.8) | 0.043 | 842 (4.6) | 74 (3.8) | 0.040 | 147 (4.5) | 19 (5.4) | 0.045 |
| NSAIDs | 3322 (6.3) | 326 (5.9) | 0.019 | 1303 (7.1) | 153 (7.9) | 0.028 | 228 (6.9) | 38 (10.9) | 0.139 |
| Antiepileptic drugs | 1028 (2.0) | 200 (3.6) | 0.100 | 363 (2.0) | 42 (2.2) | 0.012 | 88 (2.7) | 4 (1.1) | 0.112 |
| Antithyroid drugs | 188 (0.4) | 17 (0.3) | 0.009 | 70 (0.4) | 15 (0.8) | 0.051 | 15 (0.5) | 8 (2.3) | 0.158 |
Abbreviations: COPD, chronic obstructive pulmonary disease; NSAID, nonsteroidal anti‐inflammatory drugs; SLE, systemic lupus erythematosus; SMD standardized mean difference.
a
Variables with SMD <0.2 were further adjusted in the model.